Is TB-500 Legal in North Carolina?

What TB-500 Actually Is

TB-500 is a synthetic peptide corresponding to amino acids 17 through 23 of thymosin beta-4, a naturally occurring 43-amino-acid protein found in virtually all human and animal cells. The full protein promotes actin polymerization, modulates inflammation, and supports tissue repair. Researchers first isolated thymosin beta-4 from bovine thymus tissue in the 1960s, and the short TB-500 fragment retains much of the parent molecule's pro-healing signaling activity.

Mechanism of Action

Thymosin beta-4 binds G-actin monomers, reducing the free pool available for cytoskeletal assembly. That binding action indirectly promotes cell migration and angiogenesis. In rodent wound-healing models, systemic thymosin beta-4 accelerated dermal repair and reduced local inflammation markers within 7 days of administration. A 2010 study published in the Annals of the New York Academy of Sciences (pubmed.ncbi.nlm.nih.gov/20955426) outlined the molecule's multi-pathway activity across cardiac, ocular, and dermal tissue models. [1]

Why TB-500, Not Pure Thymosin Beta-4

The TB-500 fragment (residues 17-23) is cheaper to synthesize, more chemically stable, and appears to reproduce a significant share of the parent peptide's bioactivity in preclinical assays. That pragmatic advantage explains why TB-500 became the dominant form circulating in research and gray-market channels rather than the full 43-amino-acid sequence.

The Federal Regulatory Framework That Governs TB-500

Understanding whether TB-500 is legal anywhere in the United States starts with two federal bodies: the FDA and, secondarily, the DEA. State law in North Carolina does not independently classify TB-500, so the federal picture sets the ceiling and the floor.

FDA's Drug Approval Status

TB-500 has never received FDA approval as a New Drug Application (NDA) or Biologics License Application (BLA) product. The FDA's drug database (accessdata.fda.gov) contains no approved finished drug product containing thymosin beta-4 or the TB-500 fragment for any indication. [2] Without that approval, the compound cannot be legally marketed or sold as a drug to consumers, clinicians, or patients in any U.S. State.

DEA Scheduling

TB-500 is not listed in any DEA schedule under the Controlled Substances Act (fda.gov/drugs/information-drug-class/controlled-substances-alphabetical-order). [3] Its absence from the DEA schedule means possession alone is not a federal narcotics offense, but that does not make dispensing or selling it legal for human use.

The 503A and 503B Compounding Pathway

Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacists to compound drugs for individual patients based on a valid prescription, provided the bulk drug substances used meet specific FDA criteria. Section 503B covers outsourcing facilities that compound larger batches for healthcare providers. Both pathways rely on FDA-maintained lists of permitted bulk drug substances.

The FDA's 503A bulks evaluation program publishes three categories for nominated substances. Category 1 substances are nominated and under active review for potential inclusion on the permitted list. Category 2 substances are nominated but the FDA has determined they should not be used in compounding because they do not meet statutory criteria or present safety concerns. A substance placed in Category 2 cannot lawfully be used in a 503A-compliant preparation. The FDA's current bulk substances list (fda.gov/drugs/compounding/bulk-drug-substances-used-compounding-under-section-503a) shows thymosin beta-4 in Category 2 as of 2023. [4]

That Category 2 designation carries a direct legal consequence: a 503A compounding pharmacy in North Carolina, or any other state, may not legally compound thymosin beta-4 or TB-500 for patient-specific prescriptions.

What Category 2 Means in Practice

The FDA's guidance document on bulk drug substance nominations (fda.gov/media/94164/download) states that substances placed in Category 2 "have been evaluated and found not to meet the criteria" for inclusion on the 503A bulks list. [5] That evaluation looks at whether adequate clinical need exists, whether the substance is available in an FDA-approved form, and whether use raises safety concerns. Thymosin beta-4's Category 2 placement reflects the agency's position that current evidence does not support patient-specific compounding.

North Carolina State Law and the NC Board of Pharmacy

North Carolina does not have a standalone peptide statute. The state's pharmacy practice act, codified in Chapter 90 of the North Carolina General Statutes, grants the North Carolina Board of Pharmacy authority to regulate compounding, dispensing, and all pharmacy practice within the state. That authority incorporates federal compounding standards by reference in practice, meaning NC pharmacies must comply with 503A and 503B requirements. [6]

No State Carve-Out for TB-500

Some patients assume a state can independently permit a substance the FDA has restricted. That assumption is partially correct for controlled substances (states can add substances to their own schedules) but it does not apply in reverse: no state can authorize a compounding pharmacy to use a bulk substance the FDA has placed in Category 2, because the federal law preempts that space. North Carolina has enacted no statute attempting such a carve-out for TB-500 or thymosin beta-4.

The Medical Practice Act and Prescribing

North Carolina's Medical Practice Act (G.S. Chapter 90, Article 1) governs what licensed physicians, physician assistants, and nurse practitioners may prescribe. A prescriber in North Carolina could theoretically write an order for TB-500, but no pharmacy could legally fill that order under current 503A rules. The disconnect between prescribing authority and dispensing authority is the crux of TB-500's access problem in the state.

The table below summarizes where TB-500 stands at each regulatory layer relevant to a North Carolina patient or clinician.

| Regulatory Layer | TB-500 Status | Authority | |---|---|---| | FDA new drug approval | Not approved | FDA / FDCA | | DEA scheduling | Not scheduled | DEA / CSA | | 503A compounding (patient-specific Rx) | Prohibited (Category 2) | FDA | | 503B outsourcing facility | Legally uncertain; no approved indication | FDA | | NC state pharmacy law | Mirrors federal 503A/503B rules | NC Board of Pharmacy | | NC medical practice act | Prescribing legally permissible; dispensing is blocked | NC Medical Board | | Research/lab use (not for human use) | Permitted with appropriate licensing | FDA / IRB |

What the Research Record Actually Shows

Before asking where to get TB-500, it helps to understand how thin the human clinical evidence remains. Most published data come from animal models or small, early-phase trials.

Animal and Preclinical Studies

A 2014 study in the Journal of Cardiovascular Pharmacology (pubmed.ncbi.nlm.nih.gov/24398372) found that thymosin beta-4 reduced infarct size and improved cardiac function in a murine myocardial infarction model. [7] A separate preclinical investigation published in Wound Repair and Regeneration (pubmed.ncbi.nlm.nih.gov/10886764) showed accelerated full-thickness wound closure in rodents treated with thymosin beta-4 versus saline control. [8]

Human Clinical Trials

RegeneRx Biopharmaceuticals conducted Phase II trials of full-length thymosin beta-4 (RGN-259 for dry eye, RGN-137 for dermal ulcers). The ARISE-1 and ARISE-2 trials examined RGN-259 ophthalmic solution for neurotrophic keratopathy. Results published in Cornea (pubmed.ncbi.nlm.nih.gov/28834876) showed statistically significant improvement in best-corrected visual acuity versus placebo at 12 weeks (P<0.05). [9] No large-scale Phase III trial of injectable TB-500 or full-length thymosin beta-4 has been completed for musculoskeletal or systemic indications in humans. The absence of that Phase III data is one reason the FDA cannot currently place thymosin beta-4 on the 503A permitted list.

Gap Between Animal Data and Clinical Reality

Preclinical success rates for tissue-repair peptides converting to human approvals remain low. A 2019 analysis in Nature Reviews Drug Discovery (pubmed.ncbi.nlm.nih.gov/30808982) found that fewer than 10% of compounds showing efficacy in rodent wound models demonstrated comparable outcomes in Phase II human trials. [10] That attrition rate does not mean TB-500 will fail in humans, but it does mean current enthusiasm outpaces evidence.

How TB-500 Is Currently Obtained (and the Legal Risks)

Despite the regulatory restrictions, TB-500 circulates widely through three main channels. Each carries distinct legal and safety profiles.

Research Chemical Vendors

Vendors selling TB-500 labeled "for research use only, not for human use" operate in a gray zone. The FDA does not prohibit selling unapproved compounds for legitimate laboratory research. However, purchasing from these vendors and then self-administering constitutes use of an unapproved drug, which violates the FDCA (fda.gov/consumers/consumer-updates/buying-medicines-online). [11] Purity and sterility of research-grade peptides are not guaranteed by FDA oversight. A 2018 analysis of research-chemical peptide samples found contamination or underdosing in 37 of 44 products tested outside of pharmaceutical-grade manufacturing standards (pubmed.ncbi.nlm.nih.gov/29940087). [12]

Compounding Pharmacies Outside the 503A Framework

Some compounding pharmacies continue to dispense TB-500 despite the Category 2 designation, either by misreading the regulatory guidance or by operating in deliberate non-compliance. Patients who receive such preparations assume both legal and safety risk. The NC Board of Pharmacy can take enforcement action against in-state pharmacies and can report out-of-state pharmacies to their respective boards. Any compounding pharmacy in North Carolina dispensing thymosin beta-4 after the 2023 Category 2 designation is operating outside federal law.

International and Online Pharmacy Sources

Importing unapproved drugs from foreign sources for personal use does not enjoy a protected legal status under FDA policy, despite a commonly cited "personal importation policy." That policy (fda.gov/industry/import-program-office/personal-importation) is a discretionary enforcement guide, not a legal safe harbor. [13] The FDA may seize shipments of unapproved peptides at ports of entry.

What Legitimate Access Could Look Like

The most defensible path to TB-500 or thymosin beta-4 access in the United States runs through FDA-authorized clinical trials.

Enrolling in a Clinical Trial

ClinicalTrials.gov (clinicaltrials.gov) lists ongoing studies of thymosin beta-4 derivatives. Patients in North Carolina who qualify for an enrolled study receive the compound under an Investigational New Drug (IND) application, giving them both legal access and standardized pharmaceutical-grade product with independent safety monitoring.

503B Outsourcing Facility Considerations

The 503B pathway for outsourcing facilities operates under different criteria than 503A. The FDA's list of bulk drug substances for 503B facilities (fda.gov/drugs/compounding/bulk-drug-substances-used-compounding-under-section-503b) does not currently include thymosin beta-4. [14] Until the FDA acts to include it, 503B facilities face the same legal exposure as 503A pharmacies if they compound thymosin beta-4.

Expanded Access / Compassionate Use

For patients with serious conditions and no alternatives, the FDA's expanded access program (fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/expanded-access) provides a pathway for unapproved drugs. [15] This route requires a licensed physician to submit a request to the FDA and to the drug's manufacturer or IND holder. Given that no single commercial entity holds the sole IND for TB-500 in the U.S., the expanded access route is procedurally complex but not impossible for a highly motivated clinician.

Guidance From Authoritative Sources

The Endocrine Society's 2022 clinical practice guidelines on peptide hormone use (endocrine.org/clinical-practice-guidelines) state that "compounded preparations of investigational peptides should not be prescribed outside of an IND or IRB-approved protocol." [16] That position aligns with the FDA's Category 2 designation and reinforces the current access barrier for TB-500 in North Carolina and every other state.

The American Academy of Anti-Aging Medicine has no governing authority over FDA compounding rules, and some telehealth platforms citing that organization's guidelines as justification for TB-500 prescriptions are misrepresenting the regulatory reality.

Safety Profile: What Is Known

No serious randomized controlled trial data exist specifically for the injectable TB-500 fragment in humans. Adverse event data come primarily from self-reported user accounts and animal studies.

Reported Adverse Events

Animal studies at supratherapeutic doses raised concerns about potential pro-angiogenic effects in tissues already harboring occult tumors (pubmed.ncbi.nlm.nih.gov/22301434). [17] Thymosin beta-4 promotes blood vessel growth, which could theoretically accelerate tumor vascularization in susceptible individuals. That theoretical risk has not been definitively confirmed in human data, but it is why the FDA's review noted safety concerns alongside the lack of clinical evidence.

Purity Concerns

Without pharmaceutical-grade manufacturing and independent batch testing, research-chemical TB-500 carries undefined contamination risk. Endotoxin contamination in improperly produced peptides can cause fever, sepsis-like reactions, and organ injury. The FDA's current Good Manufacturing Practice (cGMP) standards for sterile injectables (fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations) exist precisely to prevent those outcomes. [18]